Introduction
Free Light Chains (FLCs) presence in cerebrospinal fluid (CSF) has been studied in several works regarding neurological disease, especially focusing on Multiple Sclerosis (MS). Up to date mainly used methods comprehend qualitative test such as isoelectrofocusing (IEF) followed by transfer and immunodetection [1] [2] [3] . Oligoclonal free light chains banding has been described in MS and should be correlated with disease activity. Intrathecal IgG production may be also present in patients suffering from other central nervous system (CNS) disease, but its detection by current laboratory tests is either tedious or insensitive. Because small amounts of immunoglobulins (Ig) typically enter CSF by passive transfer across the blood/CSF barrier, origin differentiation of Ig in CSF is needed before intrathecal immunoglobulin synthesis can be diagnosed [4] . This can be achieved either by calculation of the CSF/serum ratios of Ig compared with the CSF/serum ratio of albumin (Qalb), which is not synthesized intrathecally, or by the detection of so-called oligoclonal immunoglobulin bands (OCBs) in CSF [5, 6] .
Plasma cells produce an excess of kappa and lambda light chains during the production of intact Ig and these are secreted as FLCs. Due to the high fractional excretion and catabolism of the kidneys the half life of FLCs in human serum is only a few hours. Instead in CSF the clearance is slower and even a small increase of kFLCs may be noticeable. Several studies demonstrate the presence of kFLCs in the CSF [2, 7, 8] and kFLCs may be used as a prognosis marker [8] [9] [10] [11] [12] . In this study, we assessed the diagnostic accuracy of an automated nephelometric assay for kFLCs in CSF and serum. We compared it with traditional tests to detect intrathecal immunoglobulin synthesis and investigated the usefulness of this method for clinical application. Recently our laboratory investigated CSF/serum pairs from patients: the results obtained are compared with the standard oligoclonal band assessment that was taken as the reference standard for our study [13, 14] and demonstrate that the kFLCs Index is a valid tool to MS diagnosis [15] . These results are further improved through a re-evaluation of diagnoses adding to the statistics two cases that had not previously been diagnosed as MS.
Patients
We test CSF/serum pairs from 80 patients with different clinically well-documented neurological disorders. All patients had undergone an elective spinal puncture at the Neuroscience Department of the Tor Vergata University Hospital. The study protocol complied with the declaration of Helsinki (1964) .
Samples were excluded if artificial blood contamination of CSF or monoclonal bands in both CSF and serum were present. According to their diagnoses the patients were divided into three groups: group 1 (33 patients, 21 female and 12 male) patients having diseases without inflammation, patients with inflammatory diseases other than MS group 2 (22 patients, 13 female and 9 male) and patients with definitive MS group 3 (25 patients, 16 female and 9 male). Diagnosis of MS was established according to the McDonald criteria [16] .
Methods
OCBs were determined by immunofixation (Hydragel9 CSF Isofocusing; Sebia, Bagno a Ripoli, FI, Italia) on a semiautomated agarose electrophoresis system (Sebia Hydrasys) [13, 14] . The gels were evaluated for the presence of OCBs by three independent operators. Nephelometric measurement of kFLCs was performed with the N Latex FLC kappa Kit (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany) based on monoclonal antibodies, that recognizes hidden epitopes in intact Ig.
FLCs in CSF and serum samples were measured according to the manufacturer's protocol on the BN Prospec automated analyzer (Siemens Healthcare); the lower detection limit for kFLCs is 0.035 mg/L.
Calibrators and controls were provided by the manufacturer and consisted of stabilized human sera containing polyclonal kFLCs; calibrators and controls were diluted to the appropriate concentrations for serum and CSF determinations. CSF/serum quotients are calculated to evaluate the passively diffusion into the liquor of the FLCs that are also present in serum. An additional factor to consider is the permeability of the blood/CSF barrier. FLCs concentration increases with augmented blood-CSF barrier permeability. The CSF/serum quotient of the kFLCs was therefore plotted against the Q alb , because albumin is only synthesized in liver and diffuses just passively into the CSF. The hyperbolic function commonly used to detect the limit between diffusion and synthesis of FLCs in the CSF is: Reiber [17] , an optimal fit of the hyperbolic curve may be achieved using the following parameters: a/b = 6.5; b 2 × 10 6 = 5; c × 10 3 = 1.
kFLC Index was calculated as
Statistical analysis
Data were analyzed with Origin 7 (Origin Lab Corporation, Northampton, USA) and SPSS 17.0 (IBM Corporation, New York, USA) software. ANOVA followed by Bonferroni's test was used to determine the significance of the differences between the three groups. A p value of < 0.05 was considered significant.
Results
CSF/serum pairs of 80 patients of the neurological clinic were examined. Patient characteristics and patient groups are shown in Table 1 All patients from group 1 and group 2, have a kappafree light chain concentrations in CSF below the cutoff of 0.4 mg/L [15] . All data of the kFLC concentrations in CSF of the group 3 are above the cut off value and shows a statistically significant difference respect the group 1 and 2, for details see Figure 1 .
kFLCs serum quotients were plotted logarithmically against the albumin CSF serum quotients to determine the influence of the blood CSF barrier (Fig. 2) . Using the quotient diagram, intrathecal kappa free light chain production was identified in one patient of group 2. All patients from group 1 lie below the hyperbolic dividing line. Only one patient of group 3 lie below the Reiber function.
The use of kFLC Index calculated as kFLC CSF /kFLC serum Q albumina × 1000 that takes into account the function of the blood/CSF barrier, it's a tentative to increase the diagnostic accuracy of kFLC determination and to better assess the presence of intrathecal immunoglobulin synthesis avoiding false positive.
The Table 2 ). These are recent data obtained by a new diagnosis of two patients previously diagnosed as leukoencephalitis and revaluated as MS. The two patients are women and have a kFLC Index of 26.6 and 154 respectively, values much higher than the previously published cut-off > 12 [15] .
Finally we correlate all methods of intrathecal immunoglobulin synthesis detection with clinical diagnoses and found new values for clinical sensitivity and specificity as shown in Figure 3 .
From our data the calculation of kFLC Index shows the highest clinical sensitivity and specificity (96% and 91% respectively) to evaluate MS patients; whereas IgG Index highlights the lowest sensitivity (60%) as previously reported in literature [18] . All statistical results are shown in Table 3 . 
Discussion
In this study, we described the use of the kFLC Index using a highly sensitive latex-enhanced nephelometric automated immunoassay for detection of immunoglobulin kFLC in every paired serum and CSF samples. It has been known for decades that kFLC levels are elevated in the CSF of MS patients [5, 6] . Development of a sensitive immunoassay for serum or CSF FLC determination has allowed incorporation of FLC analysis into routine laboratory diagnostic algorithms.
We found for kFLC Index a sensitivity of 96% and a specificity of 91% for MS diagnosis.
kFLC Index more than lambda FLC index was associated with MS in accordance with previous studies using either qualitative or quantitative methods [1, 10, 19] . We establish that kFLC index is more sensitive than IgG index for found intrathecal immune production.
The determination of free immunoglobulin light chains has been technically difficult in the past, operator depending and not feasible in routine clinical diagnostics. Thus, daily assays would be easily integrated into laboratory processes reducing tedious manual procedures and uncertainty in result interpretation. Furthermore, the assay turnaround time is no more than 1.5 hours for this assay, compared with at least 4-5 hours for OCBs determination and can give us a quantification of kFLCs synthesis.
Our previous data [15] , has been further improved thanks to a reevaluation of two patients subsequently confirmed with a MS diagnosis. The current study suggest the implementation of kFLC Index determination as a screening method in CSF analysis before further investigation for a possible intrathecal immune response, especially where MS or CIS is suspected.
Our data support even more the use of the kFLC Index to MS diagnose in comparison to the classical methods. These results lead us to introduce kFLC Index test in the CSF diagnostic examinations and to support clinician in a rapid and accurate MS diagnosis.
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